A Phase I Trial of WP1066 in Patients with Recurrent Malignant Glioma and Brain Metastasis from Melanoma
MD Anderson Study Status
STAT3 Inhibitor WP1066
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma, Recurrent Malignant Glioma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.